These results might be explained by a) CRP in general not being a typical SLE activity marker; b) the confounding effects of different therapeutic regimes with usually highest corticosteroid doses on top of treatment with biologicals and DMARDs in patients with elevated disease activity, which is also found in our study (Supplementary Table 4); c) weight loss being a frequent clinical sign of active disease (B symptoms). This evidence concerns the gene CRP and systemic lupus erythematosus.